REFERENCES
- Houston, JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–1479
- IPCS (International Programme on Chemical Safety of the World Health Organization) 2001. Guidance Document for the Use of Data in Development of Chemical-Specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability in Dose/ Concentration–Response Assessment. Available at http://www.ipcsharmonize.org/csaf-intro.html.
- Kedderis, GL. 1997. Extrapolation of in vitro enzyme induction data to humans in vivo. <i>Chem Biol Interact 107:109–121
- Lipscomb, JC, Fisher, JW, Confer, PD, and Byczkowski, JZ. 1998. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. Toxicol Appl Pharmacol 152:376–387
- Lipscomb, JC, Garrett, CM, and Snawder, JE. 1997. Cytochrome P450-dependent metabolism of trichloroethylene: Interindividual differences in humans. Toxicol Appl Pharmacol 142, 311–318.
- Lipscomb, JC and Kedderis, GL. 2002. Incorporating human interindividual biotransforma-tion variance in health risk assessment. Sci Tot Environ 288:13–21.
- Lipscomb, JC, Teuschler, LK, Swartout, JC, Striley, CAF, and Snawder, JE. 2003. Variance of Microsomal Protein and Cytochrome P450 2E1 and 3A Forms in Adult Human Liver. Toxicol Mech Methods. 13:45–51.
- Murray, FJ and Andersen, ME. 2001. Data-derived uncertainty factors: boric acid (BA) as an example. Hum Ecol Risk Assess 7:125–138
- Nesaretnam K, Corcoran D, Dils RR, Darbre P. 1996. 3,4,3',4'-Tetrachlorobiphenyl acts as an estrogen in vitro and in vivo. <i>Mol Endocrinol 10:923–936
- Smallwood, CL, Swartout, J, and Lipscomb, JC. 2001. Using data to replace default uncertainty factors for boron reference dose. Presented at the annual meeting of the Society for Risk Analysis, Seattle, WA, December 2001.
- Snawder, JE and Lipscomb, JC. 2000. Interindividual variance of cytochrome P450 forms in human hepatic hicrosomes: correlation of individual forms with xenobiotic metabolism and implications in risk assessment. Regul Toxicol Pharmacol 32:200–209
- Soldin OP, Braverman LE, and Lamm SH. 2001. Perchlorate clinical pharmacology and human health: a review. Ther Drug Monit 23:316–331
- Umemura T, Takagi A, Sai K, Hasegawa R, and Kurokawa Y. 1998. Oxidative DNA damage and cell proliferation in kidneys of male and female rats during 13-weeks exposure to potassium bromate (KBrO3). Arch Toxicol 72:264–9.
- US EPA (U.S. Environmental Protection Agency). 1994. Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry. EPA/600/8-90/066F. Office of Research and Development, Washington, DC.